Immunotherapy Cost in India — What a Full Course Actually Comes To

Immunotherapy in India is priced per cycle, not as a package. As of August 2026, one cycle of a checkpoint inhibitor costs roughly ₹50,000 to ₹1,50,000 for a domestically made or biosimilar product, and roughly ₹2,00,000 to ₹4,50,000 for an imported reference product. Administration and tests add a little more.

All figures are indicative only, as of August 2026, and are quoted by product class rather than by brand. The real number for you depends on the molecule your oncologist selects, whether the dose is flat or calculated by body weight, the cycle interval, and the centre. Immunotherapy is given as day care at CION centres, so a routine cycle carries no inpatient bed charge.

There is no single full-course price, because courses run for different lengths. On three-weekly dosing, six cycles is about four months, one year is about seventeen cycles, and the two-year ceiling used in many protocols is about thirty-five cycles. Multiply the per-cycle band by the number of cycles to get your working range.

These are drug costs only, indicative as of August 2026. Add day-care administration and pre-cycle tests for every cycle. Add a response-assessment scan roughly every eight to twelve weeks — response-assessment PET-CT is coordinated at partner imaging centres rather than owned by CION, and runs roughly ₹10,000 – ₹25,000 per scan depending on the scan type, indicative as of August 2026.

A day-care cycle bill covers the drug, the chair and nursing time, the IV set, pre-medication and the observation period. It does not cover pre-cycle blood tests, response-assessment scans, biomarker testing before you start, treatment of an immune-related side effect, supportive medicines, or your travel and stay.

Ask for an itemised estimate before the first cycle that separates the drug from everything else, and ask what happens to the estimate if a side effect needs treating. If a quote arrives as a single number with no breakdown, it is not yet an estimate you can plan a year around.

Six things move the number: which molecule is prescribed, whether a biosimilar exists for it, whether the dose is flat or calculated by body weight, the cycle interval, how long treatment continues, and whether immunotherapy is given alone or alongside chemotherapy. The centre and the city matter far less than any of these.

Of these, the biosimilar question is the one worth raising at the very first consultation, because it is the only lever that can change the number without changing the treatment plan. What that entry has actually saved Indian families is set out in Biosimilars and Generic Entry: How Much Can You Actually Save?

Most families use a combination, not one source: private insurance where the policy allows it, a government scheme up to its package ceiling, a manufacturer access programme where one exists, a biosimilar instead of the reference product, and family funds for the gap. None of these is certain to apply to you.

• Private health insurance — day-care infusion is payable under most modern policies, but sub-limits, waiting periods, pre-existing-disease clauses and pre-authorisation rules decide what you actually receive. What insurers do and do not pay is set out in Does Health Insurance Cover Immunotherapy in India?
• Government schemes — Aarogyasri, CGHS, ECHS and ESI work on fixed package ceilings. High-cost immunotherapy drugs commonly sit above those ceilings, so cover is often partial or absent. Confirm the current ceiling with the treating hospital scheme desk.
• Manufacturer access programmes — several manufacturers run patient-assistance or dose-support programmes in India. Eligibility varies, documentation takes time, and applications usually have to be made before treatment starts.
• Choosing a biosimilar where one exists — the largest single reduction available to most families, and a clinical conversation to have with your oncologist rather than a decision to make alone.
• Clinical trials — in some trials the investigational drug is supplied by the sponsor. This is not a funding route to count on: eligibility is narrow, enrolment is never assured, and a trial is entered for clinical reasons.
• The planned stopping point — how long treatment runs is a clinical decision, but it is fair to ask early what the planned stopping point is and what the team does when it is reached.

These pages go deeper into the parts this one only summarises: city-level ranges, what biosimilar entry has actually saved, how insurers treat immunotherapy claims, and how the treatment itself is delivered.

• Immunotherapy Cost in Hyderabad: Indicative Ranges — the same question answered for one city, with centre-level and scheme-desk detail.
• Biosimilars and Generic Entry: How Much Can You Actually Save? — the biggest lever in the tables above, examined properly.
• Does Health Insurance Cover Immunotherapy in India? — sub-limits, waiting periods and what to confirm in writing before cycle one.
• Immunotherapy at CION Cancer Clinics — how eligibility review, day-care treatment and monitoring are run as one pathway.

Decisions for Healing, Not Billing

Cost is discussed openly at the first consultation, including the option of not starting immunotherapy at all if the numbers do not work for your family.